JPH038361B2 - - Google Patents
Info
- Publication number
- JPH038361B2 JPH038361B2 JP58135089A JP13508983A JPH038361B2 JP H038361 B2 JPH038361 B2 JP H038361B2 JP 58135089 A JP58135089 A JP 58135089A JP 13508983 A JP13508983 A JP 13508983A JP H038361 B2 JPH038361 B2 JP H038361B2
- Authority
- JP
- Japan
- Prior art keywords
- sugar
- gel permeation
- permeation chromatography
- bond
- observed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 235000000346 sugar Nutrition 0.000 claims description 22
- 150000004676 glycans Chemical class 0.000 claims description 20
- 229920001282 polysaccharide Polymers 0.000 claims description 20
- 239000005017 polysaccharide Substances 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 238000005227 gel permeation chromatography Methods 0.000 claims description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 241000125175 Angelica Species 0.000 claims description 11
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 239000007864 aqueous solution Substances 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 239000000470 constituent Substances 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 241000196324 Embryophyta Species 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 239000000243 solution Substances 0.000 claims description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 8
- 239000003960 organic solvent Substances 0.000 claims description 8
- 239000002244 precipitate Substances 0.000 claims description 8
- 238000005199 ultracentrifugation Methods 0.000 claims description 8
- 241000208173 Apiaceae Species 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 7
- 238000005481 NMR spectroscopy Methods 0.000 claims description 7
- 238000000862 absorption spectrum Methods 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 239000003125 aqueous solvent Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 208000024891 symptom Diseases 0.000 claims description 5
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 4
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 238000001962 electrophoresis Methods 0.000 claims description 4
- 238000000921 elemental analysis Methods 0.000 claims description 4
- 229930182830 galactose Natural products 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 230000002209 hydrophobic effect Effects 0.000 claims description 4
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 claims description 4
- 230000003287 optical effect Effects 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 238000011033 desalting Methods 0.000 claims description 3
- 238000000108 ultra-filtration Methods 0.000 claims description 3
- 229910002804 graphite Inorganic materials 0.000 claims 3
- 239000010439 graphite Substances 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 150000008163 sugars Chemical class 0.000 claims 2
- 230000000694 effects Effects 0.000 description 9
- 239000007924 injection Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 206010003445 Ascites Diseases 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 201000007270 liver cancer Diseases 0.000 description 6
- 208000014018 liver neoplasm Diseases 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- 230000004130 lipolysis Effects 0.000 description 5
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 4
- 101800000414 Corticotropin Proteins 0.000 description 4
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 4
- 229960000258 corticotropin Drugs 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000544270 Angelica acutiloba Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 208000022531 anorexia Diseases 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000004255 ion exchange chromatography Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 238000005377 adsorption chromatography Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000002366 lipolytic effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 101800000263 Acidic protein Proteins 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Landscapes
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58135089A JPS6028933A (ja) | 1983-07-26 | 1983-07-26 | 新規な多糖体、その製造法、及び該多糖体を有効成分とする癌症状改善剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58135089A JPS6028933A (ja) | 1983-07-26 | 1983-07-26 | 新規な多糖体、その製造法、及び該多糖体を有効成分とする癌症状改善剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6028933A JPS6028933A (ja) | 1985-02-14 |
| JPH038361B2 true JPH038361B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1991-02-05 |
Family
ID=15143571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58135089A Granted JPS6028933A (ja) | 1983-07-26 | 1983-07-26 | 新規な多糖体、その製造法、及び該多糖体を有効成分とする癌症状改善剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6028933A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100252194B1 (ko) * | 1997-10-10 | 2000-04-15 | 박호군 | 참당귀에서분리한신규한펙틴질다당류와그분리정제방법및그의면역증강제로서의용도 |
| KR100413964B1 (ko) * | 2000-10-06 | 2004-01-13 | 주식회사 에이티엔씨 | 강활추출물 또는 이로부터 분리한 화합물을 포함하는 암치료 및 예방을 위한 조성물 및 그의 분리 방법 |
| KR100413051B1 (ko) * | 2000-10-06 | 2003-12-31 | 주식회사 에이티엔씨 | 강활 추출물 또는 이로부터 분리한 화합물을 포함하는전립선 질환 치료 및 예방을 위한 조성물 및 그의 분리 방법 |
| KR20030003669A (ko) * | 2001-03-24 | 2003-01-10 | 주식회사 메덱스바이오 | 강활 추출물을 유효성분으로 하는 다이옥신 유사물질에대한 길항성 조성물 |
| CN103864947A (zh) * | 2014-03-17 | 2014-06-18 | 重庆医科大学 | 当归多糖的分离提取工艺及其应用 |
-
1983
- 1983-07-26 JP JP58135089A patent/JPS6028933A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6028933A (ja) | 1985-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS62209101A (ja) | エキナセアプルプレアまたはエキナセアアングステイフオリアの細胞培養物からの免疫刺激作用性ポリサツカライド、その製造方法及びこれを含む製剤 | |
| JPH045652B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| HU185314B (en) | Process for producing water-soluble immunostimulant glyco-proteins from klebsiella pneumoniae | |
| CN105175569B (zh) | 从金花茶叶中提取金花茶多糖的方法 | |
| CN114404462B (zh) | 一种组合物及其在制备具有治疗胃损伤和/或胃溃疡作用的药物中的应用 | |
| JPH038361B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| CN105315383B (zh) | 由双孢蘑菇罐头加工废水中提取纯化的活性多糖及其提取纯化工艺以及应用 | |
| CN105153324A (zh) | 金花茶多糖的提取方法 | |
| JPS6049164B2 (ja) | 血漿増量剤 | |
| JP3157728B2 (ja) | 糖尿病治療薬 | |
| EP1498131B1 (en) | Medicinal preparation containing phenylethanoid glycosides extracted from Cistanche tubulosa | |
| US6475520B1 (en) | Pharmaceutical composition with low toxicity for anti-inflammation and anti-exudation | |
| JP3161882B2 (ja) | 丹参由来多糖類、その製造法および用途 | |
| JPS5939403B2 (ja) | 抗トロンビン様薬剤 | |
| JP3984288B2 (ja) | 青しょう子由来の予防・治療用組成物 | |
| JPS6213927B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| CN101250233A (zh) | 红花桑寄生多糖的提取方法 | |
| JP3638967B2 (ja) | ネフローゼ症候群及び肝障害症状の寛解剤 | |
| JPH09176206A (ja) | ミコバクテリウム・ツベルクロシスから抽出した複合多糖体およびその製造方法 | |
| JP3194254B2 (ja) | 血糖降下機能剤の製造方法 | |
| JPS6338325B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| JP3382623B2 (ja) | 血管弛緩剤の組成物 | |
| US3922263A (en) | Hypoglycemic compound and method of preparing | |
| US3950518A (en) | Hypoglycemic composition and method of use | |
| CN1038818A (zh) | 口服药物牛滕多糖的生产方法 |